Table 1

Demographic characteristics of study participants

ParticipantsClinical studies (study 1)
(n = 386)Ex vivo studies (study 2)
(n = 67)
Age (years)65.8 ± 0.565.5 ± 1.3
Male sex83.797.0
Hypertension68.976.1
Hyperlipidemia62.477.6
Type 2 diabetes32.926.9
Smoking status
 Active22.84.4
 Ex-smoker46.659.7
BMI (kg/m2)27.7 ± 0.229.4 ± 0.5
Cholesterol (mg/dL)177.3 ± 2.4146.9 ± 12.4
Glucose (mg/dL)125.4 ± 3.197.2 ± 5.4
Insulin (μU/mL)15.49 ± 1.4313.98 ± 2.01
HOMA-IR5.39 ± 0.543.36 ± 0.03
HDL (mg/dL)38.8 ± 0.642.5 ± 7.7
Triglycerides (mg/dL)141.4 ± 4.9149.7 ± 40.7
Hemoglobin (g/dL)13.3 ± 0.113.7 ± 0.2
White blood cell count (cells/µL)7,288 ± 1518,553 ± 749
Platelet count (cells/µL)239,782 ± 4,224225,900 ± 8,100
Creatinine (mg/dL)1.07 ± 0.020.94 ± 0.04
rs266717 alleles
 CC23.2
 CT48.1
 TT28.7
rs17366568 alleles
 AA1.3
 AG18.5
 GG80.2
Medication
 ACEi58.546.2
 ARB9.816.4
 β-Blocker75.388.0
 Aspirin/clopidogrel82.193.6
 Statins78.288.0
 CCB24.941.7
  • Data are reported as the mean ± SEM or %. ACEi, ACE inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker.